TACR1 and hepatoblastoma: Aprepitant and cytostatics (doxorubicin, cisplatin) showed a synergic antitumor action against hepatoblastoma cells, and a synergic effect was also reported in osteosarcoma cells when the NK-1R antagonist L-733,060 was co-administered with cytostatics such as cisplatin, ifosfamide, mitomycin, adriamycin; however, this effect was not reported in non-malignant human embryonic kidney 293 cells [88,151].